Get started
Author

Semih Şeker

Observed name: Semih Seker
ORCID: 0000-0002-8957-2050
Observed ORCID: 0000-0002-8957-2050
OpenAlex ID: A5087087729
Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line
2010 · Azmi Yerlikaya, Emrah Okur, et al. · Molecular Medicine Reports · 31
PDF
Label-free nLC-MS/MS proteomic analysis reveals significant differences in the proteome between colorectal cancer tissues and normal colon mucosa
2023 · Sezgin Zeren, Semih Seker, et al. · Medical Oncology · 3
Comparative Analysis of Acquired Resistance to Bortezomib in Prostate Cancer Cells Using Proteomic and Bioinformatic Tools
2025 · Semih Seker, Betul Sahin, et al. · Journal of Cellular and Molecular Medicine · 1
PDF
The Senescence Program is Reduced in Proteasome Inhibitor Bortezomib-Resistant PC3 Prostate Cancer Cell Line
2023 · Ertan Kanbur, Semih Şeker, et al. · European Journal of Biology · 1
HRI Kinase Modulation by BTdCPU as a Therapeutic Strategy for Bortezomib Resistance in Prostate Cancer
2026 · Semih Seker, Emrah Okur, et al. · Current Medicinal Chemistry
Proteozom İnhi̇bi̇törü Mg132’ni̇n 4t1 Meme Ve B16f10 Melanoma Kanser Hücreleri̇ndeki̇ Si̇totoksi̇k Etki̇leri̇
2009 · Azmi Yerlikaya, Harun Dokudur, et al. · DergiPark (Istanbul University)
Works count: 6
Citation count: 36
H-index: 2
I10-index: 1
Year
Topic
Type